Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report

Hasan Nassereldine1†, Razan Mohty2†, Hussein Awada1, Iman Abou Dalle2, Jean El-Cheikh2 and Ali Bazarbachi2*

Abstract
Background: Mantle cell lymphoma is the rarest subtype of non-Hodgkin’s lymphoma. It can exhibit diverse extranodal manifestations. However, renal involvement is uncommon, and if it occurs, it usually only gets detected post-mortem. There are several mechanisms by which mantle cell lymphoma can damage the kidneys. Renal failure is a potential complication, and prompt evaluation and diagnosis are critical steps to prevent long-term complications.

Case presentation: We present the case of a 75-year-old non-Hispanic White male with past medical history significant for hypertension and dyslipidemia, presenting with fever, weight loss, and night sweats. Work-up showed markedly elevated white blood cells, multiple enlarged lymph nodes, and a kidney mass. The patient was diagnosed with mantle cell lymphoma with kidney involvement confirmed with a kidney biopsy. His disease was positive for cyclin D1 overexpression despite t(11; 14) absence. The patient received six cycles of alternating vincristine, rituximab, cyclophosphamide, doxorubicin, and prednisone then dexamethasone, high-dose cytarabine, and oxaliplatin, after which he was maintained on ibrutinib and rituximab, with resolution of symptoms and disease regression.

Conclusion: We present a case of a rare presentation of Mantle cell lymphoma while describing the clinical presentation and diagnostic and treatment approaches. This case report can assist physicians in the clinical work-up and treatment of patients with similar diagnosis or presentation.

Keywords: Non-Hodgkin’s lymphoma, Renal manifestation, Hematological malignancy, Renal failure, Case report

Background
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) that accounts for 2.5–6% of all NHL. It is characterized by the propagation of monoclonal lineage of mature B-lymphocytes [1] and associated with t(11;14)(q13;q32) gene translocation leading to overexpression of the cell-cycle regulatory protein cyclin D1 [2]. MCL is a disease of the older population with median age at onset of 60 years [3–5]. The median overall survival (OS) of these patients is around 3–5 years [6, 7]. Approximately 80% of patients have advanced stage at diagnosis, with the most common sites of extranodal involvement being the bone marrow, liver, spleen, Waldeyer’s ring, and gastrointestinal tract [3, 8, 9]. Conversely, kidney involvement is very rare and is often underdiagnosed. However, the increase in the incidence and survival of those patients, in the last few decades, has allowed for such uncommon manifestations to become more apparent [10]. The mechanism by which the disease can affect the kidneys are various and might be due to direct infiltration, urinary tract obstruction, or as a consequence of paraneoplastic syndrome, leading to a wide differential of presentations including acute kidney injury, nephrotic syndrome, glomerulopathy, or acute
tubule-interstitial nephritis [10, 11]. In this paper, we describe a case of an elderly patient with cyclin D1-positive, t(11;14)-negative MCL with kidney involvement at diagnosis.

**Case presentation**
A 75-year-old non-Hispanic White male with past medical history significant for hypertension and dyslipidemia presented with 1-month history of flu-like illness characterized by fever reaching 38.5 °C, nonproductive cough, weight loss, and occasional night sweats. The patient denied any skin rashes, change in bowel movements, urinary symptoms, or joint pain. The patient is a nonsmoker with no history of alcohol intake and additionally reports no family history of malignancies. Physical examination on presentation was pertinent for diffuse wheezing and rhonchi in addition to abdominal distention and bilateral axillary lymphadenopathy; the patient had no apparent skin changes. The patient had no financial difficulties and was addressed with his preferred native language of Arabic. Upon admission, his complete blood count (CBC) showed elevated white blood cell (WBC) count (18,400/μL) and low hemoglobin (Hb) (6.4 g/dL), for which he received 2 units of packed red blood cells (pRBCs). Notably, he was found to have an elevated creatinine level (5.9 reaching 6.5 mg/dL) and low albumin (2.8 g/dL). Hemo-

lytic work-up was negative (Table 1).

A computed tomography (CT) scan showed features of pneumonia, bilateral abnormal axillary lymph nodes (LN), splenomegaly (22 cm), and scattered abnormal LN across the abdomen and pelvis. Ultrasound (US)-guided axillary LN core biopsy revealed cells positive for CD5, CD20, CD23, and cyclin D1 but negative for CD3 and CD10, with Ki-67 of 15% suggestive of MCL. Immunofluorescence study showed diffuse mesangial hypercellularity, tubular atrophy, interstitial fibrosis, focal chronic inflammation with few plasma cells, and atypical lymphoid infiltrate positive for CD20 and cyclin D1. Immunofluorescence study showed diffuse mesangial positivity for IgA (Fig 1A, B). Such findings were consistent with acute tubular injury and acute interstitial nephritis due to renal involvement by a known MCL.

The patient received six cycles of alternating vincristine, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx). His treatment was complicated by recurrent admissions for pneumonia and febrile neutropenia. Disease evaluation after four cycles of treatment by PET scan showed resolution of supra- and infradiaphragmatic disease with a Deauville score of 1 (Fig 1C). End-of-treatment evaluation showed no FDG-avid disease, with complete resolution of the kidney mass with uptake in the upper poles of the kidney. Follow-up studies showed improvement in kidney function as evidenced by a creatinine level now ranging between 3.1 and 3.6 mg/dL. He was started on rituximab maintenance. After 3 months of follow-up, PET scan showed increased uptake in the kidneys without another lymphadenopathy. He was started on ibrutinib, a Bruton tyrosine kinase inhibitor, in addition to continuation of rituximab. PET scan after 3 months of ibrutinib with rituximab showed complete remission with a Deauville score of 3. A timeline of the patient’s disease course is presented in Fig 2.

**Table 1** Summary of relevant laboratory results

| Laboratory test       | Result          | Reference range          |
|-----------------------|-----------------|--------------------------|
| WBC                   | 18,400/μL       | 4000–11,000/μL           |
| Hemoglobin            | 6.4 g/dL        | 12.0–18.0 g/dL           |
| Creatinine level      | 5.9–6.5 mg/dL   | 0.5–1.0 mg/dL            |
| Albumin level         | 2.8 g/dL        | 36–53 g/L                |
| Beta-2 microglobulin  | 8.98 mg/L       | 0.80–2.40 mg/L           |
| Direct Coombs test    | Negative        | Negative                 |
| Reticulocyte count    | 1.25%           | 0.2–2.0%                 |
| Indirect bilirubin    | 0.1 mg/dL       | 0.2–0.8 mg/dL            |
| Haptoglobin           | 2.69 mg/dL      | 0.30–2.00 g/L            |
| LDH                   | 209 IU/L        | 110–265 IU/L             |
| Peripheral smear      | No schistocytes | No abnormal cells        |

WBC white blood count, LDH lactate dehydrogenase

**Discussion**
Our patient had dual acute tubular injury and interstitial nephritis secondary to lymphomatous renal parenchymal invasion. Lymphoid infiltration is one of the main
pathological mechanisms by which NHL, particularly MCL, directly affects kidneys, and it is often asymptomatic [12]. In one of the largest case series of autopsies conducted on lymphoma patients, it was found that 34% of patients had renal lymphoid infiltration, of which only 14% were detected before death [13]. Indeed, renal failure

Fig. 1  Kidney biopsy results: A Focal tubular atrophy and a glomerulus with cellular crescent are noted. B The interstitial compartment shows, in addition to the inflammatory cell infiltrate, aggregates of monomorphic neoplastic lymphoid cells. PET-CT scan C on the left image showing a mass on the lower pole of the left kidney (yellow crosshair). Right image of PET-CT scan shows resolution of the mass after 3 months of chemotherapy.

Fig. 2  Timeline of symptom onset, patient diagnosis, and treatment.
occurs in only 0.5% of these patients, and most of them do not develop signs of volume overload or flank pain, which explains its underdiagnosis [12]. Renal failure is thought to develop because of increased pressure within the parenchyma that results from lymphocyte invasion, as shown in our patient. This hypothesis is supported by studies underlining the concomitant improvement in renal function and decrease in kidney size after starting chemotherapy, though in most patients renal function fails to recover back to baseline [14]. Correspondingly, our patient’s renal function began to improve after starting treatment of MCL, and his serum creatinine level stabilized at a range higher than his baseline, which could be explained by the multifactorial aspects of his renal failure. The presence of a chronic element of kidney disease with 40% fibrosis on the biopsy will obviously remain as a cause of his chronic kidney disease. Also, the presence of paraproteinemia and long-standing hypertension could in part participate in his renal failure. Hence, controlling his blood pressure is essential to achieve long-term kidney function control. Although kidney function starts to recover gradually once MCL treatment is initiated, patients with such overt renal failure require immediate and focused kidney management. In addition to IV hydration, administration of immunosuppressive therapy and corticosteroids allows for rapid improvement in renal function. Nevertheless, temporary renal replacement therapy may still be necessary in some cases while adequate renal function is being restored [15, 16].

Although the presence of t(11;14) is characteristic of MCL diagnosis, it is not a necessary finding for establishing the disease diagnosis [17]. Indeed, several reports and studies have provided evidence of MCL overexpressing cyclin D1 in the absence of t(11;14) [17, 18]. Our patient’s lymph node biopsy was positive for CD5, CD20, CD23, and cyclin D1 on flow cytometry. The finding of cyclin D1 does not alter the diagnosis of MCL. While the overexpression of this marker is associated with t(11;14), evidence in literature suggests that this is not always the case [19, 20]. Although CD23 is not a common finding in MCL, it is still one of the frequently described immunophenotypic variants of MCL [21].

Conclusion

Finally, although rare, renal involvement by MCL should always be included in the differential diagnosis when a patient with MCL presents with renal function impairment. Imaging can be very useful; however, the diagnosis might necessitate kidney biopsy for confirmation in some cases. Prompt evaluation and treatment are important to prevent long-term sequelae. Clinicians should focus on preservation of kidney function through treatment of MCL first, then focus on exacerbating factors including blood pressure and blood sugar control, and avoidance of nephrotoxins. Kidney function recovers, albeit partially, once MCL treatment is initiated.

Acknowledgements

None.

Author contributions
HN, IM, and HA collected the data, reviewed the literature, and drafted the manuscript. IAD, JAC, and AB reviewed and edited the final draft. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
The patient provided written and verbal consent ahead of drafting the manuscript.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Faculty of Medicine, American University of Beirut, Beirut, Lebanon. 2 Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, P.O. Box 113-6044, Beirut, Lebanon.

Received: 25 January 2022   Accepted: 24 May 2022
Published online: 30 June 2022

References
1. Weisenburger DD, Armitage JO. Mantle cell lymphoma— an entity comes of age. Blood. 1996;87(11):4483–94.
2. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol. 2006;24(1):22–7. https://doi.org/10.1002/hon.767.
3. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009;114(8):1469–76. https://doi.org/10.1182/blood-2009-02-179739.
4. Weisenburger DD, Vose JM, Greiner TC, Lynch JC, Chan WC, Bierman PJ, Dave BJ, Sanger WG, Armitage JO. Mantle cell lymphoma: A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol. 2000;64(3):190–6.
5. Ladha A, Zhao J, Epner EM, Pu JJ. Mantle cell lymphoma and its management: where are we now? Exp Hematol Oncol. 2019;8:2. https://doi.org/10.1186/s40164-019-0136-0.
6. Leux C, Maynadie M, Troussard X, Cabrera Q, Herry A, Le Guyader‑Peyrou S, Le Gouill S, Monnereau A. Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol. 2014;93(8):1327–33. https://doi.org/10.1007/s00277-014-2049-5.
7. Oinonen R, Fransila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer. 1998;34(3):329–36. https://doi.org/10.1016/s0959-8499(97)10056-9.
8. Ishibashi M, Yamamoto K, Kudo S, Chen KR. Mantle cell lymphoma with skin invasion characterized by the common variant in the subcutis and
blastoïd transformation in the overlying dermis. Am J Dermatopathol. 2010;32(2):180–2. https://doi.org/10.1097/DAD.0b1013e3181b2ed67.

9. Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Pinis MA, Vallespi T, Woessner S, Montserrat E. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82(3):567–75. https://doi.org/10.1002/(sici)1097-0142(19980201)82:3<567::aid-cncr203>3.0.co;2-z.

10. Bello L, Quercia AD, Daidola G, Burdese M, Colla L, Basso E, Karvela E, Marcuccio C, Tarella C, Segoloni GP. Lymphomatous renal involvement: G Ital Nefrol. 2010;27(Suppl 3):S34-39.

11. Davies N, Pollard A, Cohen Y, Amir G, Darmon D, Kleinman Y, Goldfarb AW, Ben-Yehuda D. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol. 2001;67(3):158–64. https://doi.org/10.1043/1600-0609.2001.5709049.x.

12. Cohen LJ, Rennke H, Laubach JP, Humphreys BD. The spectrum of kidney involvement in lymphoma: a case report and review of the literature. Am J Kidney Dis. 2010;56(6):1191–6. https://doi.org/10.1053/j.ajkd.2010.07.009.

13. Richmond J, Sherman RS, Diamond HD, Craver LF. Renal lesions associated with malignant lymphomas. Am J Med. 1962;32:184–207. https://doi.org/10.1016/S0002-9343(62)80289-9.

14. Tornroth T, Heiro M, Marcussen N, Franssila K. Lymphomas diagnosed by percutaneous kidney biopsy. Am J Kidney Dis. 2003;42(5):960–71. https://doi.org/10.1053/j.ajkd.2003.08.004.

15. Davies J, Healey DA, Wood KM, Jones K, Kanagasundaram NS. Acute renal failure due to mantle cell lymphoma—a case report and discussion of the literature. Clin Nephrol. 2007;67(6):394–6. https://doi.org/10.5414/cnp67.394.

16. Colak N, Dede F, Canbakan B, Odabas AR, Akyurek N. Acute tubulo-interstitial nephritis associated with mantle cell lymphoma. Eur J Haematol. 2011;87(4):341–5. https://doi.org/10.1111/j.1440-1797.2011.01758.x.

17. Hunt KE, Reichard KK, Wilson CS. Mantle cell lymphoma lacking the t(11;14) translocation: a case report and brief review of the literature. J Clin Pathol. 2008;61(7):689–70. https://doi.org/10.1111/j.1365-2572.2007.08426.x.

18. Sander B, Quintanilla-Martinez L, Ott G, Keri I, Kuzi J, Chan JK, Svedlow SH, Campo E. Mantle cell lymphoma—a spectrum from indolent to aggressive disease. Virchows Arch. 2016;468(3):245–57. https://doi.org/10.1007/s00438-015-1840-6.

19. Vela-Chávez T, Adam P, Kremer M, Bink K, Bacon CM, Menon G, Ferry JA, Hunt KE, Reichard KK, Wilson CS. Mantle cell lymphoma lacking the t(11;14) translocation: a case report and brief review of the literature. J Clin Pathol. 2008;61(7):689–70. https://doi.org/10.1111/j.1365-2572.2007.08426.x.

20. Fend F, Jaffe ES, Quintanilla-Martinez L. Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without overt immunoblastic transformation in the overlying dermis. Am J Dermatopathol. 2010;32(2):180–2. https://doi.org/10.1097/DAD.0b1013e3181b2ed67.

21. Redaelli A, Barillari S, Lombardi A, Pugliese L, Pessina G, Zangarini M. Cyclin D1-positive diffuse large B-cell lymphoma: a clinicopathological study. Haematologica. 2010;95(2):245–9. https://doi.org/10.3324/haematol.2010.027353.

22. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Eriksson M, Nordstrom M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen JG, Möller J, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford RJ, Stilgenbauer S, Messmer K, Velds A, Jukema JW, van de Velde H, Cavalli F, Investigators LYM. Bortezomib-based therapy for newly diagnosed mantle cell lymphoma. N Engl J Med. 2015;372(10):944–53. https://doi.org/10.1056/NEJMoa1412066.

23. Hermine O, Hoster E, Walewski J, Bosly A, Szer G, Beaux B, de Vosset P, Dimopoulos MA, Cavalli F, Investigators LYM. Bortezomib-based therapy for newly diagnosed mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte Blood. 2013;121(1):48–53. https://doi.org/10.1182/blood-2011-09-373020.

24. Delarue R, Hainoun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, Van Hoof A, Casellas N, Brousse N, Leprêtre F, Hermeine O, Groupe d’Etude des Lymphomes de l’Adulte Blood. 2013;121(1):48–53. https://doi.org/10.1182/blood-2011-09-373020.

25. Robat K, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylpynenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F, Investigators LYM. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–53. https://doi.org/10.1056/NEJMoa1412066.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.